Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jared Bailey

Vascular & Interventional Radiology Pocatello, ID Medical Doctor

NPI 1891929519 CMS profile 872716

777 Hospital Way, Pocatello, ID 83201

Open in the dashboard

General payments

$2,850

43 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jared Bailey of Pocatello, ID is reported in the CMS Open Payments database as having received $2,850 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $273 7
2024 General $417 14
2023 General $164 3
2022 General $77 2
2021 General $78 5
2020 General $63 2
2019 General $1,779 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jared Bailey
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Jared Bailey were reported at $273. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Jared Bailey Vascular & Interventional Radiology median Middle half National median
2019 $1,779 $422 $125–$1,555 $163
2020 $63 $200 $68–$652 $114
2021 $78 $280 $99–$866 $132
2022 $77 $433 $137–$1,497 $149
2023 $164 $506 $152–$2,019 $160
2024 $417 $556 $175–$1,930 $164
2025 $273 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $2,042 14 payments
  2. Inari Medical, Inc. $448 12 payments
  3. Boston Scientific Corporation $102 4 payments
  4. Medtronic, Inc. $88 4 payments
  5. Stryker Corporation $57 3 payments
  6. Cook Medical LLC $36 1 payment
  7. W. L. Gore & Associates, Inc. $34 2 payments
  8. Abbott Laboratories $20 1 payment
  9. Bard Peripheral Vascular, Inc. $15 1 payment
  10. Sirtex Medical Inc $8 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $1,476 4 payments
  2. Food and Beverage $1,374 39 payments
Products named General payments · program years 2019–2025
  1. Penumbra System Neurointervention $1,838 6 payments
  2. Indigo $915 4 payments
  3. FLOWTRIEVER CATHETER, S $481 14 payments
  4. CT THROMBECTOMY SYSTEM KIT $481 14 payments
  5. Penumbra System Neurointervention $225 5 payments
  6. RUBY Coil $57 1 payment
  7. VENASEAL $50 2 payments
  8. OBSIDIO $49 1 payment
  9. KYPHON EXPRESS II KYPHOPAK TRAY $37 2 payments
  10. Cook Medical Zilver PTX $36 1 payment
  11. Other $155 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

33

Median for Diagnostic Radiology: 24

Drug cost

$15,917

Median for Diagnostic Radiology: $190

Branded share of claims

100%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 19 $15,838
Clopidogrel Clopidogrel Bisulfate Brand 14 $79

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 221 billing codes

Paid by Medicare

$105,967

Of which drugs: $289

Medicare patients

1,182

Average age 74

Services billed

3,673

602 women, 580 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 35%
Ischemic heart disease 32%
Chronic kidney disease 31%
Depression 30%
Heart failure 23%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 16 1,675 $172

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record